Dyadic International (NASDAQ:DYAI) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Dyadic International (NASDAQ:DYAI) announced its earnings results on Wednesday. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01), FiscalAI reports. The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative return on equity of 695.96% and a negative net margin of 239.67%.

Here are the key takeaways from Dyadic International’s conference call:

• Dyadic said it is transitioning from a platform company to a more commercial biotech, with products now launched, shipped, sampled, and beginning to generate revenue through direct sales, OEM distribution, milestone payments, and partnerships.
• Q1 2026 revenue rose 182% year over year to about $1.1 million, driven largely by higher R&D and grants-related activity, while the net loss improved modestly to about $1.95 million.
• The company highlighted multiple commercialization wins, including Proliant’s launch of AlbuFree DX, Enzymes’ commercial launch of recombinant bovine chymosin, and first commercial shipments of DNase I and transferrin through its IBT Bioservices distribution agreement.
• Management said customer interest is increasing across life sciences, food and nutrition, and industrial markets, including initial purchase orders in cultivated meat and expanded sampling in Asia-Pacific and Europe through partners like Intralink and FermBox Bio.
• Dyadic ended the quarter with about $6.6 million in cash, restricted cash, and investment-grade securities, and management reiterated that existing resources should fund operations into Q2 2027 if cash burn stays near recent levels.

Dyadic International Price Performance

Shares of NASDAQ:DYAI traded down $0.00 during midday trading on Thursday, hitting $0.71. The stock had a trading volume of 28,684 shares, compared to its average volume of 65,469. The company’s 50-day moving average price is $0.82 and its 200-day moving average price is $0.88. The company has a market capitalization of $25.80 million, a P/E ratio of -2.83 and a beta of 1.18. The company has a quick ratio of 2.68, a current ratio of 2.68 and a debt-to-equity ratio of 4.08. Dyadic International has a fifty-two week low of $0.65 and a fifty-two week high of $1.35.

Hedge Funds Weigh In On Dyadic International

Several hedge funds and other institutional investors have recently made changes to their positions in DYAI. Landscape Capital Management L.L.C. acquired a new position in shares of Dyadic International in the 3rd quarter valued at approximately $190,000. Geode Capital Management LLC grew its holdings in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the last quarter. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.